Help us improve our information
We need your help to improve our information to better support people with Crohn’s and Colitis. Fill in our short survey to let us know what we're doing well and how we can better meet your needs.
Last updated: November 2024
Last full review: July 2023
Next review date: July 2026
This information is for people with Crohn’s or Colitis who are on risankizumab (Skyrizi) treatment or who are thinking about starting it. Our information can help you decide if this treatment is right for you. It looks at:
This information is about risankizumab in general. It should not replace advice from your IBD team.
We need your help to improve our information to better support people with Crohn’s and Colitis. Fill in our short survey to let us know what we're doing well and how we can better meet your needs.
If you have any concerns about risankizumab treatment, contact your IBD team.
The brand name for risankizumab is Skyrizi.
Risankizumab is an antibody that’s made by living cells in a lab. It is a type of biologic medicine.
Antibodies are proteins that recognise and stick to specific targets. Risankizumab sticks to a target called IL-23. Your immune system naturally makes IL-23 to help you fight infections. But in people with Crohn’s or Colitis, it can also cause inflammation. Risankizumab blocks the effects of IL-23. This reduces gut inflammation. But, like many other treatments for Crohn’s or Colitis, it also alters your immune system.
Risankizumab can only be prescribed by a specialist in a hospital. It aims to get your condition under control and keep it under control.
The National Institute of Health and Care Excellence (NICE) has recommended risankizumab as a treatment option for people over 16 years with moderately to severely active Colitis in England. NICE is the organisation that decides whether treatments should be available on the NHS in England. Wales and Northern Ireland usually follow NICE decisions too. The Scottish Medicines Consortium (SMC) is the organisation that decides for Scotland. Risankizumab is not yet being assessed by the SMC to decide if it should be available for people with Colitis on the NHS in Scotland.
Your IBD team might suggest it for you if you have Colitis and:
Risankizumab is used to treat over 16s in England, Scotland and Wales with moderate to severely active Crohn’s. In Northern Ireland it is used to treat over 18s, although it can sometimes be given to 16- and 17-year-olds if biologic medicines are not suitable.
Your IBD team might suggest it for you if you have Crohn’s and:
Risankizumab is also used to treat a skin condition called psoriasis, and arthritis linked to psoriasis.
There are lots of things to think about when you start a new treatment. Your IBD team will discuss your options with you. They might give you a choice of different treatments. You should consider the potential benefits, possible risks, and the goals of your treatment together. Things to consider include:
You could use our Medicines Tool to help you think about your options. Or our appointment guide, which includes a list of questions you might want to ask. It can help you focus on what matters most to you. We also have full information on other medicines or surgery that you might find helpful.
Use this tool to understand more about potential treatment options that suit your needs. The tool is designed to help you:
Risankizumab can be effective at improving symptoms and keeping your condition under control. But it does not work for everyone. It is not possible for your doctor to predict which treatment will suit you best. Different medicines work for different people. It may take some time to find the right medicine for you. Find out more about taking medicines.
At first, the aim of risankizumab treatment is to reduce the inflammation in your gut and get your condition under control. This is called induction treatment. Once your condition is under control, the treatment aims to keep it under control. This is called maintenance treatment.
Some clinical trials look at how well a medicine works as induction treatment. Some look at how well it works as maintenance treatment. Some look at how well it works for both. We do not always have the same information for different medicines or different conditions. But we will include it when we do.
The people in the trials are given risankizumab or a placebo. A placebo is a substance that looks the same as the treatment but does not have any medicine in it.
These results come from two large clinical trials which compared risankizumab and placebo as induction treatment. Everybody in the trials had already been treated with Crohn’s medicines that had not worked or had stopped working. Some of them had already been treated with biologic medicines. Some had not.
The table below shows how well the recommended dose of risankizumab got Crohn’s under control after 12 weeks of treatment.
How well risankizumab got Crohn’s under control
Icon key: each person represents around 5%
More people had their Crohn’s under control after taking risankizumab compared to people taking placebo. Around 44 in every 100 people (44%) had their Crohn’s under control after 12 weeks of risankizumab treatment. Around 22 in every 100 people (22%) taking placebo had their Crohn’s under control after 12 weeks. But not everyone responded to risankizumab.
In clinical trials of risankizumab, people whose Crohn’s improved after 12 weeks of treatment either carried on taking risankizumab or switched to placebo for maintenance treatment. It’s important to know that not everyone in these trials had their Crohn’s in remission at the start of maintenance treatment.
The table below shows how many people had their Crohn’s completely under control after a year of maintenance treatment.
How well risankizumab kept Crohn’s under control
Icon key: each person represents around 5%
More people had their Crohn’s completely under control after taking risankizumab maintenance treatment than after taking placebo maintenance treatment. Around 52 in every 100 people (52%) still had their Crohn’s under control after taking risankizumab for a year. This included people who had not responded to biologic medicines in the past. But not everyone carried on responding to risankizumab.
These results come from one large clinical trial of risankizumab induction treatment. The trials compared risankizumab to placebo in people with moderate to severely active Colitis. Everybody in the trials had already been treated with Colitis medicines that had not worked or had stopped working. Some of them had already been treated with biologic medicines. Some had not.
The table below shows how well the recommended dose of risankizumab got Colitis under control after 12 weeks of treatment.
Icon key: each person represents around 5%
More people had their Colitis under control after taking risankizumab compared to people taking placebo. Around 20 in every 100 people (20%) had their Colitis under control after 12 weeks of risankizumab treatment. Around 6 in every 100 people (6%) taking placebo had their Colitis under control after 12 weeks. But not everyone responded to risankizumab.
People who responded to 12 weeks of risankizumab treatment either carried on taking risankizumab or switched to placebo for maintenance treatment. For maintenance treatment, the trial looked at how well risankizumab kept Colitis under control after another 52 weeks of treatment.
The table below shows how well risankizumab kept Colitis completely under control in people whose Colitis was completely under control after induction treatment.
Icon key: each person represents around 5%
More people had their Colitis completely under control after taking risankizumab maintenance treatment than after taking placebo maintenance treatment. Around 61 in every 100 people (61%) still had their Colitis under control after taking risankizumab for a year. But not everyone carried on responding to risankizumab.
There have not been any clinical trials that compared risankizumab directly to other medicines for Crohn’s or Colitis.
Everyone responds differently to a new medicine. Most people who respond to risankizumab start feeling better within 4 to 12 weeks. In some people it could take longer. Some people might not respond at all.
You cannot take risankizumab by mouth because it is broken down by the gut, which stops it working. Instead, you have it through an intravenous infusion (drip) for your first three doses, and then as an injection under your skin.
Risankizumab comes in a box containing one cartridge of medicine and one on-body injector. The cartridge and injector are single-use only.
You must keep risankizumab in the fridge at a temperature of 2°C to 8°C. Do not freeze it. You can keep it out of the fridge for up to 24 hours, but at no more than 25°C. Keep it in its box to protect it from light.
Do not use any doses that are past their expiry date or have ever been frozen, even if they have thawed. Your pharmacist can tell you how to dispose of them.
Your doctor or nurse will teach you how to inject yourself with risankizumab. The Patient Information Leaflet also contains detailed instructions on what to do. This is in the box. It is sometimes called a Package Leaflet. You can also get it online: Patient Information Leaflet for risankizumab injection.
Using the on-body injector might seem a bit daunting at first. But in clinical trials, over 9 in 10 people who used it said it was easy or very easy to use from the first dose.
One of the common side effects of risankizumab is pain and redness at the injection site. These tips can help:
Check your skin afterwards
When you remove the on-body injector, there might be a few drops of liquid on your skin and the injection site might bleed slightly. Press a cotton wool ball or pad over the injection site for about 10 seconds.
For your first three doses, you have 600mg of risankizumab every 4 weeks. These are the doses you have in hospital through a drip.
After this, all the rest of your doses are 360mg. This is one cartridge of medicine that you have through an on-body injector every 8 weeks. If you miss a dose, take it as soon as you remember.
For your first three doses, you have 1200mg of risankizumab every 4 weeks. These are the doses you have in hospital through a drip.
After this, all the rest of your doses will be either 180mg or 360mg. This is one cartridge of medicine that you have through an on-body injector every 8 weeks. If you miss a dose, take it as soon as you remember.
If you respond to risankizumab and have no serious side effects, you are likely to carry on taking it for at least a year. Every year, your IBD team should assess you to check whether continuing risankizumab is the best option. If you, or your IBD team, feel that it is no longer right for you, you should discuss other treatment options together.
There are a few reasons why you or your IBD team might think about stopping or changing your treatment:
Do not stop taking risankizumab without discussing it with your IBD team.
If risankizumab is no longer the best treatment for you, your IBD team should discuss other treatment options with you. You should consider the potential benefits, possible risks, and the goals of your treatment together.
In clinical trials, it was safe to take risankizumab alongside steroids. The clinical trials did not look at whether it was safe to take it alongside other immunosuppressants or biologic medicines. Your IBD team will talk to you about whether you need to take other medicines.
Do not stop steroid treatment without talking to your IBD team.
Having treatment that alters your immune system makes you more likely to get infections. And it may cause any inactive infections you have in your body to become active again. Before you start risankizumab, your IBD team will do thorough checks to make sure it’s suitable for you. They may:
If you have an infection, you might need to delay starting risankizumab until it’s been treated.
You should not take risankizumab if you have active TB. If you have underlying, inactive TB, it needs to be treated before you start risankizumab.
You should wait 4 weeks after having any live vaccines before you can start risankizumab. You should not have any live vaccines until at least 21 weeks after your last dose of risankizumab.
After you start risankizumab, you should have regular checks to see how well it is working. Your IBD team will ask about your symptoms, any side effects you may be getting, and how you’re managing with the injections. They will also check for any signs of infection. You might have blood tests and faecal calprotectin testing. Your IBD team will tell you what checks you need and how often.
Once you’ve got used to risankizumab, you should have a check-up every year. This is to check if you are still responding to risankizumab or whether you need to change the dose or stop treatment.
Risankizumab alters your immune system, so your body might not fight off infections as well as other people. You might get more infections than you used to. Or they might last longer or be more serious than usual.
Up to 1 in every 10 people taking risankizumab might get a cold, a cough or a throat or sinus infection. Up to 1 in every 100 people taking risankizumab might get skin infections.
Contact your GP or NHS 111 straight away if you think you have an infection
Signs to look out for include:
If you have an infection, you may need urgent treatment. Your IBD team might advise you to stop taking risankizumab until you are better.
To reduce your risk of getting an infection, try to avoid close contact with people who have infections. It’s sensible to wash your hands often, especially before meals and after using the toilet. And take care to store and prepare food safely.
All medicines can have side effects, but not everyone gets them. Some side effects can happen right away, others might happen later.
Some side effects are mild and may go away on their own or after you stop taking risankizumab. Others may be more serious and could need treatment. Some side effects might mean that the risankizumab is not right for you.
In clinical trials, the risk of getting side effects was similar in people taking risankizumab to people taking dummy treatment.
Speak to your IBD team if you get any side effects.
We also encourage you to report any side effects to the Medicines and Healthcare Products Regulatory Agency (MHRA). You can do this through the Yellow Card scheme online or by downloading the MHRA Yellow Card app. This helps collect important safety information about medicines.
Some people might get serious side effects that need urgent treatment. These do not happen often, but it is important to know what to look out for.
Rarely, people taking risankizumab might have an allergic reaction. In clinical trials, this happened to less than 1 in every 100 people taking risankizumab.
Call 999 if you have difficulty breathing or swallowing
Contact NHS 111 straight away if you think you have any other signs of an allergic reaction
Signs to look out for include:
After the allergic reaction has been treated, contact your IBD team to let them know what has happened.
Here, we list the most common side effects of risankizumab. These might affect 1 to 10 in every 100 people taking risankizumab:
This is not a full list of side effects. There is information about less common side effects of risankizumab in the Patient Information Leaflet. This is also called a Package Leaflet. It should be in the box with your medicine. You can also get it online: Patient Information Leaflet for risankizumab injection.
There is no evidence that risankizumab interacts with other medicines. But it’s always best to check first.
Speak to your doctor or pharmacist if you’re taking, or plan to take, any other medicines. This includes medicines you buy from a pharmacy or supermarket, as well as herbal, complementary, or alternative medicines.
Live vaccines are made using weakened versions of living viruses or bacteria. If you have a lowered immune system, there is a possibility they might cause infections. Live vaccines used in the UK include:
If someone you live with is due to have a live vaccine, ask your IBD team if you need to take any precautions.
Everyone with Crohn’s or Colitis taking a biologic medicine should be invited to have the flu vaccine every year. You may be advised to have the pneumococcal vaccine. You are also eligible for all doses of COVID-19 vaccination. These are not live vaccines.
We have not found any clinical trials that looked at the best time to have vaccinations in relation to your risankizumab dose.
Risankizumab did not have harmful effects on pregnancy or fertility during studies on animals. But we do not know how it affects pregnancy or fertility in humans.
We have separate information about Reproductive health and Pregnancy and breastfeeding.
We do not know if risankizumab passes into breastmilk.
In theory, it is likely to pass into breastmilk in very low levels. It is also likely to be destroyed in your baby’s gut so most of it will not be absorbed into their bloodstream. But this has not been tested so we do not know for sure.
If you are thinking about breastfeeding while you’re taking risankizumab, talk to your IBD team. They can help you weigh up the benefits of breastfeeding during treatment against the possible risks.
We have separate information about Pregnancy and breastfeeding.
There is no evidence that drinking alcohol affects the way your body deals with risankizumab. But to keep the health risks from alcohol low, it is best to keep to recommended limits.
Taking medicines and managing side effects can be difficult – we understand and we’re here to help. Our Helpline can answer general questions about treatment options and can help you find support from others with the conditions.
Your IBD team are also there to help. You can talk to them about your dosage, how they’ll be monitoring you and what other options there might be. You should also get in touch with your IBD team if you have any new symptoms or side effects.
It can take time to find the medicine that’s right for you. Don’t be afraid to ask questions and seek out extra support when you need it.
This information is general and does not replace specific advice from your health professional. Talk to your GP or IBD team for information that’s specific to you.
We follow strict processes to make sure our information is based on up-to-date evidence and easy to understand.
Please email us at evidence@crohnsandcolitis.org.uk if:
You can also write to us at Crohn’s & Colitis UK, 1 Bishop Square, Hatfield, AL10 9NE, or contact us through our Helpline: 0300 222 5700
Treatments
Read information
Surgery and complications
Read information
We know it can be difficult to live with, or support someone living with these conditions. But you’re not alone. We provide up-to-date, evidence-based information and can support you to live well with Crohn’s or Colitis.
Our helpline team can help by:
Providing information about Crohn’s and Colitis.
Listening and talking through your situation.
Helping you to find support from others in the Crohn’s and Colitis community.
Providing details of other specialist organisations.
Please be aware we’re not medically or legally trained. We cannot provide detailed financial or benefits advice or specialist emotional support.
Please contact us via telephone, email or LiveChat - 9am to 5pm, Monday to Friday (except English bank holidays).
If you need specific medical advice about your condition, your GP or IBD team will be best placed to help.
Would you like to save the changes made to this page?
Your details were successfully saved.